263 related articles for article (PubMed ID: 36338701)
1. Meeting an un-MET need: Targeting MET in non-small cell lung cancer.
Michaels E; Bestvina CM
Front Oncol; 2022; 12():1004198. PubMed ID: 36338701
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Patil T; Staley A; Nie Y; Sakamoto M; Stalker M; Jurica JM; Koehler K; Cass A; Kuykendall H; Schmitt E; Filar E; Reventaite E; Davies KD; Nijmeh H; Haag M; Yoder BA; Bunn PA; Schenk EL; Aisner DL; Iams WT; Marmarelis ME; Camidge DR
JTO Clin Res Rep; 2024 Feb; 5(2):100637. PubMed ID: 38361741
[TBL] [Abstract][Full Text] [Related]
3. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R; Benjamin DJ; Nagasaka M
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509224
[TBL] [Abstract][Full Text] [Related]
4. Lung Cancer with
Fujino T; Suda K; Mitsudomi T
Lung Cancer (Auckl); 2021; 12():35-50. PubMed ID: 34295201
[No Abstract] [Full Text] [Related]
5. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
Wang K; Du R; Roy-Chowdhuri S; Li ZT; Hong L; Vokes N; Elamin YY; Hume CB; Skoulidis F; Gay CM; Blumenschein G; Fossella FV; Tsao A; Zhang J; Karachaliou N; O'Brate A; Gann CN; Lewis J; Rinsurongkawong W; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Altan M; Le X
JTO Clin Res Rep; 2023 Aug; 4(8):100533. PubMed ID: 37649681
[TBL] [Abstract][Full Text] [Related]
6. The Treatment of a New Entity in Advanced Non-Small Cell Lung Cancer: MET exon 14 Skipping Mutation.
Rocco D; Della Gravara L; Palazzolo G; Gridelli C
Curr Med Chem; 2023 Aug; ():. PubMed ID: 37534484
[TBL] [Abstract][Full Text] [Related]
7. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
8. A narrative review of MET inhibitors in non-small cell lung cancer with
Santarpia M; Massafra M; Gebbia V; D'Aquino A; Garipoli C; Altavilla G; Rosell R
Transl Lung Cancer Res; 2021 Mar; 10(3):1536-1556. PubMed ID: 33889528
[TBL] [Abstract][Full Text] [Related]
9. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
10. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
Fraser M; Seetharamu N; Diamond M; Lee CS
Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971
[TBL] [Abstract][Full Text] [Related]
11. INSIGHT 2: a phase II study of tepotinib plus osimertinib in
F Smit E; Dooms C; Raskin J; Nadal E; Tho LM; Le X; Mazieres J; S Hin H; Morise M; W Zhu V; Tan D; H Holmberg K; Ellers-Lenz B; Adrian S; Brutlach S; Schumacher KM; Karachaliou N; Wu YL
Future Oncol; 2022 Mar; 18(9):1039-1054. PubMed ID: 34918545
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
13. Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC.
Jørgensen JT; Mollerup J
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565287
[TBL] [Abstract][Full Text] [Related]
14. Current and future treatment options for
Hong L; Zhang J; Heymach JV; Le X
Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
[TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer with
Yang M; Mandal E; Liu FX; O'Hara RM; Lesher B; Sanborn RE
Front Oncol; 2023; 13():1241402. PubMed ID: 38273845
[TBL] [Abstract][Full Text] [Related]
16. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
17. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
18.
Terlecka P; Krawczyk P; Grenda A; Milanowski J
J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945842
[TBL] [Abstract][Full Text] [Related]
19. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
20. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
